Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.33 USD
Change Today +0.0184 / 5.94%
Volume 20.0K
GNWSF On Other Exchanges
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

genenews ltd (GNWSF) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/4/14 - $1.64
52 Week Low
04/23/15 - $0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENENEWS LTD (GNWSF)

Related News

No related news articles were found.

genenews ltd (GNWSF) Related Businessweek News

No Related Businessweek News Found

genenews ltd (GNWSF) Details

GeneNews Limited, a molecular diagnostics company, focuses on the development and application of functional genomics to enable early diagnosis and personalized health management based on disease specific biomarkers. Its principal platform technology, the Sentinel Principle, detects and stages various diseases or medical conditions from a blood sample. The company is applying the Sentinel Principle in the areas of cancer, arthritis, cardiovascular diseases, and neurological disorders. Its lead product includes ColonSentry, a blood-based molecular test to aid physicians in determining an individual’s risk of having colorectal cancer. The company was formerly known as ChondroGene Limited and changed its name to GeneNews Limited in October 2006. GeneNews Limited was founded in 1998 and is headquartered in Markham, Canada.

4 Employees
Last Reported Date: 03/31/15
Founded in 1998

genenews ltd (GNWSF) Top Compensated Officers

Executive Chairman, Member of Compensation & ...
Total Annual Compensation: --
Chief Financial Officer, Treasurer, Director ...
Total Annual Compensation: C$131.3K
Executive Vice President of US Corporate Deve...
Total Annual Compensation: C$198.6K
Compensation as of Fiscal Year 2013.

genenews ltd (GNWSF) Key Developments

GeneNews Limited Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

GeneNews Limited announced earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenues of approximately CAD 701,000 as compared to CAD 37,000 in the same period in 2013. The net loss was approximately CAD 2.3 million, or CAD 0.04 loss per common share, as compared to a net loss of approximately CAD 2.5 million, or CAD 0.07 loss per common share, for fourth quarter of 2013. For the year, the company reported net loss of approximately CAD 7.7 million or CAD 0.14 loss per common share, as compared to a net loss of approximately CAD 9.4 million, or CAD 0.31 loss per common share for the year ended December 31, 2013. The approximate CAD 1.7 million decrease in net loss was primarily due to an increase in total revenues in the current year, the elimination of research and development spending, and the non-recurring nature of restructuring and related costs that were recorded in 2013 and decreases in sales and marketing expenses. These factors were partially offset by an increase in its share of IDL losses and in general and administrative expenses.

GeneNews Limited Auditor Raises 'Going Concern' Doubt

GeneNews Limited filed its Annual on Mar 31, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Genenews Limited Announces Earnings Results for the Third Quarter Ended September 30, 2014

GeneNews Limited announced earnings results for the third quarter ended September 30, 2014. For the quarter, the company's total revenues were approximately CAD 1.1 million as compared to CAD nil in the same period in 2013. The net loss for the third quarter of 2014 was approximately CAD 0.9 million, or CAD 0.02 loss per common share, as compared to a net loss of approximately CAD 3.4 million, or CAD 0.10 loss per common share, for the same three-month period in 2013.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNWSF:US $0.33 USD +0.0184

GNWSF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GNWSF.
View Industry Companies

Industry Analysis


Industry Average

Valuation GNWSF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.6x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENENEWS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at